rivaroxaban

02/15/2013 - "However, the phase III trial of low-dose rivaroxaban demonstrated a significantly reduced incidence of recurrent vascular events without an increased risk of fatal bleeding. "
01/01/2009 - "Notably, the superior efficacy of rivaroxaban was achieved with a low but not significant increase in the incidence of major bleeding episodes. "
06/01/2015 - "The management of life-threatening bleeding associated with rivaroxaban remains a challenge for physicians due to the lack of evidence about clinically effective options for anticoagulation reversal. "
07/01/2015 - "Thus, the objective of this pilot study was to assess postoperative bleeding events observed in clinical practice in patients receiving rivaroxaban after undergoing THA and TKA and to compare their results with those published in the RECORD trials. "
10/01/2014 - "The addition of rivaroxaban increased the incidence of "clinically relevant" bleeding episodes, as defined in the study protocol (11.2% of patients per year in the rivaroxaban group versus 6.4% in the placebo group), as well as the incidence of major bleeding events (respectively 1.2% and 0.3% of patients per year) and intracranial haemorrhage (14 versus 5 cases). "

11/30/2012 - "New oral anticoagulant direct Xa factor inhibitor rivaroxaban has a good therapeutic efficacy in prevention (primary and secondary) of stroke in AF patients. "
03/01/2015 - "This case underlines the need for further studies on the safety of thrombolysis in stroke patients taking rivaroxaban. "
01/01/2015 - "Therefore, we assumed that patients may benefit from rivaroxaban if treated soon after TIA or minor stroke, and designed this adequately powered randomized study, TRACE. "
01/01/2015 - "This trial is to evaluate the feasibility of early anticoagulation with rivaroxaban in acute ischemic stroke or TIA patients with nonvalvular AF. "
09/01/2014 - "Based primarily on the ROCKET AF trial results, the US Food and Drug Administration recently approved the use of rivaroxaban for stroke prophylaxis in patients with nonvalvular AF. "

09/01/2015 - "Venous thromboembolism can be safely and effectively treated by rivaroxaban, and does of 15 mg twice daily for 21 days followed by 20 mg once daily for 3 months are superior to the other 2 tested therapy regimen in this patient cohort."
01/01/2012 - "Dabigatran and rivaroxaban have also been shown to be effective in the treatment of acute venous thromboembolism. "
01/01/2011 - "Our study demonstrates the need for further randomised controlled clinical trials to be conducted to assess the safety and efficacy of rivaroxaban in clinical practice, focusing on the surgical complications as well as the potential prevention of venous thromboembolism."
01/01/2010 - "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in phase-II and phase-III trials involving over 24,000 patients. "
06/01/2008 - "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in Phase II and Phase III trials involving over 24,000 patients. "

03/01/2015 - "The safety and efficacy of rivaroxaban in the periprocedural anticoagulation for patients undergoing catheter ablation of atrial fibrillation is not well established. "
01/15/2016 - "Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,362 patients."
11/01/2014 - "The postmarketing surveillance registry evaluated the safety and efficacy of rivaroxaban in Japanese patients with atrial fibrillation (AF) treated with rivaroxaban. "
09/01/2014 - "The efficacy of rivaroxaban in patients with atrial fibrillation."
01/01/2013 - "Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment."

01/01/2015 - "Rivaroxaban, particularly in the acute phase of pulmonary embolism, may be considered an effective and safe therapeutic choice even in elderly patients, a population less represented in clinical trials."
04/05/2012 - "A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. "
06/01/2015 - "PK studies provided evidence that malabsorption of rivaroxaban 20 mg due to irregular intake of meals during shift work was the leading cause of recurrent pulmonary embolism. "
03/01/2015 - "The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients. "
03/01/2015 - "Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study."